Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.61 |
| ▸ | CCR1 | P32246 | 3/20 | 0.44 |
| ▸ | CCR5 | P51681 | 3/20 | 0.44 |
| ▸ | CCR8 | P51685 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM4B | O94953 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.42 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128890 | 0.85 | MECP2 (0.53) | SLC2A1CCR1CCR5CCR8KDR | |
| SCHEMBL2885850 | 0.84 | CDK2 (0.49) | SLC2A1CCR1CCR5CCR8KDR | |
| Hydrochloric Acid SCHEMBL4891120 | 0.84 | SLC2A1 (0.62) | SLC2A1CCR1CCR5CCR8KDR | |
| SCHEMBL3134667 | 0.83 | SLC2A1 (0.42) | SLC2A1CCR1CCR5CCR8KDM4E | |
| SCHEMBL3134265 | 0.83 | SLC2A1 (0.42) | SLC2A1CCR1CCR5CCR8KDR | |
| SCHEMBL3138619 | 0.82 | SLC2A1 (0.41) | SLC2A1CCR1CCR5CCR8KDR | |
| Hydrochloric Acid SCHEMBL3134658 | 0.81 | SLC2A1 (0.41) | SLC2A1CCR1CCR5CCR8KDR | |
| SCHEMBL3134700 | 0.80 | SLC2A1 (0.44) | SLC2A1CCR1CCR5CCR8KDR | |
| SCHEMBL3142922 | 0.80 | CYP2A6 (0.51) | SLC2A1SMN1; SMN2HTTNPC1MAPT | |
| SCHEMBL3136919 | 0.80 | KDR (0.45) | SLC2A1CCR1CCR5CCR8KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | SLC2A1 1451/4885CCR1 4835/4885CCR5 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.